World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
106
Citations
61466
World Ranking
6381
National Ranking
362

Overview

Andreas Schneeweiss is affiliated with the German Cancer Research Center in Germany. Their research primarily focuses on oncology and cancer-related studies, contributing extensively to the fields of Medicine as well as Biochemistry, Genetics, and Molecular Biology. The main subfields in which they are active include Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics, and Radiology, Nuclear Medicine, and Imaging.

Their work centers on a range of cancer-related topics, notably:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Cancer Cells and Metastasis

Schneeweiss has contributed to numerous publications across reputable journals. Frequent venues for their research publications include:

  • Annals of Oncology (50 publications)
  • Cancer Research (44 publications)
  • Geburtshilfe und Frauenheilkunde (42 publications)
  • Senologie - Zeitschrift für Mammadiagnostik und -therapie (39 publications)
  • Journal of Clinical Oncology (19 publications)

Selected recent papers authored or co-authored by Andreas Schneeweiss include:

  • "Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study," 2020, The Lancet Oncology
  • "Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer," 2021, Annals of Oncology
  • "Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials," 2021, The Lancet Oncology
  • "First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis," 2021, Annals of Oncology
  • "Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study," 2021, JNCI Journal of the National Cancer Institute

Frequent collaborators include:

  • Peter A. Fasching (179 joint publications)
  • Michael Untch (125 joint publications)
  • Volkmar Müller (121 joint publications)
  • Tanja Fehm (120 joint publications)
  • Wolfgang Janni (109 joint publications)

Best Publications

  • Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

    Peter Schmid;Stephen Y Chui;Leisha A Emens

  • Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

    Sandra M. Swain;José Baselga;Sung-Bae Kim;Jungsil Ro

  • Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    Gunter Von Minckwitz;Chiun Sheng Huang;Max S. Mano;Sibylle Loibl

  • Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

    Carsten Denkert;Gunter von Minckwitz;Silvia Darb-Esfahani;Bianca Lederer

  • Association analysis identifies 65 new breast cancer risk loci

    Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley

  • Large-scale genotyping identifies 41 new loci associated with breast cancer risk

    Kyriaki Michailidou;Per Hall;Anna Gonzalez-Neira;Maya Ghoussaini

  • Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

    A. Schneeweiss;S. Chia;T. Hickish;V. Harvey

  • Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    David W. Miles;Arlene Chan;Luc Y. Dirix;Javier Cortés

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

    Sandra M Swain;Sung-Bae Kim;Javier Cortés;Jungsil Ro

  • Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay

    Irène Baccelli;Andreas Schneeweiss;Sabine Riethdorf;Albrecht Stenzinger

  • Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

    Peter Schmid;Hope S Rugo;Sylvia Adams;Andreas Schneeweiss

  • Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

    Gunter von Minckwitz;Andreas Schneeweiss;Sibylle Loibl;Christoph Salat

  • Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

    Nasim Mavaddat;Kyriaki Michailidou;Kyriaki Michailidou;Joe Dennis;Michael Lush

  • Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women

    Leila Dorling;Sara Carvalho;Jamie Allen

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients

    Brigitte Rack;Christian Schindlbeck;Julia Jückstock;Ulrich Andergassen

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

    Stig E. Bojesen;Stig E. Bojesen;Karen A. Pooley;Sharon E. Johnatty;Jonathan Beesley

  • Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants

    Nasim Mavaddat;Paul D.P. Pharoah;Kyriaki Michailidou;Jonathan Tyrer

  • MicroRNA related polymorphisms and breast cancer risk

    Sofia Khan;Dario Greco;Dario Greco;Kyriaki Michailidou;Roger L. Milne;Roger L. Milne

Frequent Co-Authors

Michael Untch
Michael Untch Helios Klinikum Berlin-Buch
Barbara Burwinkel
Barbara Burwinkel Heidelberg University
Peter A. Fasching
Peter A. Fasching University of Erlangen-Nuremberg
Matthias W. Beckmann
Matthias W. Beckmann University of Erlangen-Nuremberg
Christian Jackisch
Christian Jackisch Breast Cancer Research Foundation
Sibylle Loibl
Sibylle Loibl Goethe University Frankfurt
Jens Huober
Jens Huober Kantonsspital St. Gallen
Tanja Fehm
Tanja Fehm Heinrich Heine University Düsseldorf
Carsten Denkert
Carsten Denkert Philipp University of Marburg
Volkmar Müller
Volkmar Müller Universität Hamburg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but want flexible study options, online nursing degrees offer a practical path. Many institutions now offer programs that allow you to earn highly respected qualifications from home. For those looking to advance their careers quickly and affordably, the cheapest nurse practitioner programs can lead to advanced clinical roles while minimizing student debt.

If you’re just starting on your journey, look into the cheapest online bsn programs for foundational nursing education. Registered nurses who already have a diploma or ADN can further their education through the cheapest rn to bsn programs, opening up more job opportunities and higher earning potential.

For those interested in leadership, research, or academic roles, pursuing a phd nursing education online can help you reach the highest levels of the nursing profession. With these online pathways, flexible and affordable options are available for every stage of your healthcare career.

Best Scientists Citing Andreas Schneeweiss

Trending Scientists

Recently Published Articles